Publication details

Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups

Authors	PAJTLER Kristian W. WITT Henrik SILL Martin JONES David T. W. HOVESTADT Volker KRATOCHWIL Fabian WANI Khalida TATEVOSSIAN Ruth PUNCHIHEWA Chandanamali JOHANN Pascal REIMAND Jueri WARNATZ Hans-Joerg RYZHOVA Marina MACK Steve RAMASWAMY Vijay CAPPER David SCHWEIZER Leonille SIEBER Laura WITTMANN Andrea HUANG Zhiqin SLUIS Peter van VOLCKMANN Richard KOSTER Jan VERSTEEG Rogier FULTS Daniel TOLEDANO Helen AVIGAD Smadar HOFFMAN Lindsey M. DONSON Andrew M. FOREMAN Nicholas HEWER Ekkehard ZITTERBART Karel GILBERT Mark ARMSTRONG Terri S. GUPTA Nalin ALLEN Jeffrey C. KARAJANNIS Matthias A. ZAGZAG David HASSELBLATT Martin KULOZIK Andreas E. WITT Olaf COLLINS V. Peter HOFF Katja von RUTKOWSKI Stefan PIETSCH Torsten BADER Gary YASPO Marie-Laure DEIMLING Andreas von LICHTER Peter TAYLOR Michael D. GILBERTSON Richard ELLISON David W. ALDAPE Kenneth KORSHUNOV Andrey KOOL Marcel PFISTER Stefan M.
Year of publication	2015
Type	Article in Periodical
Magazine / Source	Cancer Cell
MU Faculty or unit	Faculty of Medicine
Citation
Doi	http://dx.doi.org/10.1016/j.ccell.2015.04.002
Field	Oncology and hematology
Keywords	POSTERIOR-FOSSA EPENDYMOMAS; PEDIATRIC INTRACRANIAL EPENDYMOMAS; CENTRAL-NERVOUS-SYSTEM; NF-KAPPA-B; CHILDHOOD EPENDYMOMAS; MUTATIONS; MEDULLOBLASTOMA; SUBGROUPS; GENE; GLIOBLASTOMA
Description	Ependymal tumors across age groups are currently classified and graded solely by histopathology. It is, however, commonly accepted that this classification scheme has limited clinical utility based on its lack of reproducibility in predicting patients' outcome. We aimed at establishing a uniform molecular classification using DNA methylation profiling. Nine molecular subgroups were identified in a large cohort of 500 tumors, 3 in each anatomical compartment of the CNS, spine, posterior fossa, supratentorial. Two supratentorial subgroups are characterized by prototypic fusion genes involving RELA and YAP1, respectively. Regarding clinical associations, the molecular classification proposed herein outperforms the current histopathological classification and thus might serve as a basis for the next World Health Organization classification of CNS tumors.